Tags

Type your tag names separated by a space and hit enter

Aspirin use in relation to risk of prostate cancer.
Cancer Epidemiol Biomarkers Prev. 2002 Oct; 11(10 Pt 1):1108-11.CE

Abstract

Experimental studies have shown inhibitory effects of nonsteroidal anti-inflammatory drugs on prostate cancer cell proliferation and reduction of prostate cancer metastasis, suggesting their possible preventive role for prostate cancer. We examined the association between regular aspirin use and the risk of prostate cancer among participants in the Health Professionals Follow-up Study, a prospective cohort of 47,882 United States men who were 40-75 years of age and without a history of prostate cancer in 1986. Biennial self-administered questionnaires were used to assess regular aspirin use from 1986 to 1996. We confirmed and staged incident cases of prostate cancer according to medical records and pathology reports. During 518,072 person-years of follow-up, 2,479 new cases of prostate cancer were ascertained. Of these, 608 were diagnosed as advanced (extraprostatic) prostate cancer and 258 as metastatic prostate cancer. We found no association between aspirin use and total prostate cancer. After accounting for prostate-specific antigen examinations and other potentially confounding variables, the relative risk of total prostate cancer for aspirin users compared with nonusers was 1.05 (95% confidence interval, 0.96-1.14). For metastatic prostate cancer, we observed a suggestive decrease in risk among men reporting greater frequency of aspirin use. The multivariate relative risk of metastatic prostate cancer among men using aspirin 22 or more days/month was 0.73 (95% confidence interval, 0.39-1.38) compared with nonusers. We noted no evidence of a linear dose-response relationship (P for trend = 0.40). The results from this cohort indicate that regular aspirin use is not likely to prevent the incidence of total prostate cancer, but we cannot exclude a possible benefit of frequent aspirin use on risk of developing metastatic prostate cancer.

Authors+Show Affiliations

Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA. michael.leitzmann@channing.harvard.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12376516

Citation

Leitzmann, Michael F., et al. "Aspirin Use in Relation to Risk of Prostate Cancer." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 11, no. 10 Pt 1, 2002, pp. 1108-11.
Leitzmann MF, Stampfer MJ, Ma J, et al. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(10 Pt 1):1108-11.
Leitzmann, M. F., Stampfer, M. J., Ma, J., Chan, J. M., Colditz, G. A., Willett, W. C., & Giovannucci, E. (2002). Aspirin use in relation to risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 11(10 Pt 1), 1108-11.
Leitzmann MF, et al. Aspirin Use in Relation to Risk of Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(10 Pt 1):1108-11. PubMed PMID: 12376516.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aspirin use in relation to risk of prostate cancer. AU - Leitzmann,Michael F, AU - Stampfer,Meir J, AU - Ma,Jing, AU - Chan,June M, AU - Colditz,Graham A, AU - Willett,Walter C, AU - Giovannucci,Edward, PY - 2002/10/12/pubmed PY - 2002/12/27/medline PY - 2002/10/12/entrez SP - 1108 EP - 11 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 11 IS - 10 Pt 1 N2 - Experimental studies have shown inhibitory effects of nonsteroidal anti-inflammatory drugs on prostate cancer cell proliferation and reduction of prostate cancer metastasis, suggesting their possible preventive role for prostate cancer. We examined the association between regular aspirin use and the risk of prostate cancer among participants in the Health Professionals Follow-up Study, a prospective cohort of 47,882 United States men who were 40-75 years of age and without a history of prostate cancer in 1986. Biennial self-administered questionnaires were used to assess regular aspirin use from 1986 to 1996. We confirmed and staged incident cases of prostate cancer according to medical records and pathology reports. During 518,072 person-years of follow-up, 2,479 new cases of prostate cancer were ascertained. Of these, 608 were diagnosed as advanced (extraprostatic) prostate cancer and 258 as metastatic prostate cancer. We found no association between aspirin use and total prostate cancer. After accounting for prostate-specific antigen examinations and other potentially confounding variables, the relative risk of total prostate cancer for aspirin users compared with nonusers was 1.05 (95% confidence interval, 0.96-1.14). For metastatic prostate cancer, we observed a suggestive decrease in risk among men reporting greater frequency of aspirin use. The multivariate relative risk of metastatic prostate cancer among men using aspirin 22 or more days/month was 0.73 (95% confidence interval, 0.39-1.38) compared with nonusers. We noted no evidence of a linear dose-response relationship (P for trend = 0.40). The results from this cohort indicate that regular aspirin use is not likely to prevent the incidence of total prostate cancer, but we cannot exclude a possible benefit of frequent aspirin use on risk of developing metastatic prostate cancer. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/12376516/Aspirin_use_in_relation_to_risk_of_prostate_cancer_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=12376516 DB - PRIME DP - Unbound Medicine ER -